Trial Details
Not RecruitingBasic Information
| Clinical ID | c3376 |
|---|---|
| Identifier | EUCTR2005-002048-25-SE |
| Trial Title | A pilot study to investigate the use of recombinant cholera toxin B subunit in the treatment of active Crohn's disease. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory Bowel Disease (IBD) is the comprehensive term for disorders involving chronic inflammation in the gastrointestinal tract, often the small intestine and colon. It is believed to be a disorder mediated by T lymphocytes that arise in genetically susceptible persons as a result of a breakdown in the regulatory constraints on mucosal immune responses to enteric bacteria. Evidence suggests that Th1 T cells play an important pathogenetic role in Crohns disease. Level: PT_Classification code 10011401_ |
| Interventions | Product Name: rCTB-401 Pharmaceutical Form: Oral solution Other descriptive name: rCTB-401 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- |
Participant Information
| Sponsor | SBL Vaccin AB |
|---|---|
| City | - |
| Country/Region | Sweden |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | Not Available |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |